{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Solimando AG"],"funding":["Associazione Italiana per la Ricerca sul Cancro","Regione Puglia","Università degli Studi di Bari Aldo Moro"],"pagination":["65-74"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8863772"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Background & aims
A plethora of second-line therapies have been recently introduced for hepatocellular carcinoma (HCC) treatment with promising results. A meta-analysis of second-line treatments for HCC has been performed to better tailor their use based on improved patient stratification and to identify the best available option.Methods
Pubmed, Scopus, Web of Science, and ClinicalTrials.gov were searched for randomized controlled trials evaluating second-line treatment for advanced HCC in patients already treated with sorafenib. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS) and drug withdrawal due to adverse events. Network meta-analyses were performed considering placebo as the basis for comparison in efficacy and s"],"journal":["Clinical and experimental medicine"],"pubmed_title":["Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis."],"pmcid":["PMC8863772"],"funding_grant_id":["20441"],"pubmed_authors":["De Re V","Krebs M","Nanni O","Vacca A","Petracci E","Fasano R","Argentiero A","Brunetti O","Solimando AG","Susca N","Racanelli V","Azzali I","Silvestris N","Leone P"],"additional_accession":[]},"is_claimable":false,"name":"Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.","description":"Background & aims
A plethora of second-line therapies have been recently introduced for hepatocellular carcinoma (HCC) treatment with promising results. A meta-analysis of second-line treatments for HCC has been performed to better tailor their use based on improved patient stratification and to identify the best available option.Methods
Pubmed, Scopus, Web of Science, and ClinicalTrials.gov were searched for randomized controlled trials evaluating second-line treatment for advanced HCC in patients already treated with sorafenib. The primary outcome was overall survival (OS). Secondary outcomes were progression-free survival (PFS) and drug withdrawal due to adverse events. Network meta-analyses were performed considering placebo as the basis for comparison in efficacy and s","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-06-19T04:51:28.59Z","creation":"2025-02-19T03:26:19.325Z"},"accession":"S-EPMC8863772","cross_references":{"pubmed":["34146196"],"doi":["10.1007/s10238-021-00727-7"]}}